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OBJECTIVES This study was designed to address, in patients with severe ischemic left ventricular
dysfunction, whether dobutamine stress echocardiography (DSE) can predict improvement of
left ventricular ejection fraction (LVEF), functional status and long-term prognosis after
revascularization.
BACKGROUND Dobutamine stress echocardiography can predict improvement of wall motion after revascu-
larization. The relation between viability, improvement of function, improvement of heart
failure symptoms and long-term prognosis has not been studied.
METHODS We studied 68 patients with DSE before revascularization; 62 patients underwent resting
echocardiography/radionuclide ventriculography before and three months after revasculariza-
tion. Long-term follow-up data (New York Heart Association [NYHA] functional class,
Canadian Cardiovascular Society [CCS] classification and events) were acquired up to two
years.
RESULTS Patients with $4 viable segments on DSE (group A, n 5 22) improved in LVEF at three
months (from 27 6 6% to 33 6 7%, p , 0.01), in NYHA functional class (from 3.2 6 0.7
to 1.6 6 0.5, p , 0.01) and in CCS classification (from 2.9 6 0.3 to 1.2 6 0.4, p , 0.01);
in patients with ,4 viable segments (group B, n 5 40) LVEF and NYHA functional class
did not improve, whereas CCS classification improved significantly (from 3.0 6 0.8 to 1.3 6
0.5, p , 0.01). A higher event rate was observed at long-term follow-up in group B versus
group A (47% vs. 17%, p , 0.05).
CONCLUSIONS Patients with substantial viability on DSE demonstrated improvement in LVEF and NYHA
functional class after revascularization; viability was also associated with a favorable prognosis
after revascularization. (J Am Coll Cardiol 1999;34:163–9) © 1999 by the American College
of Cardiology
Many studies have demonstrated the use of low dose
dobutamine stress echocardiography (DSE) in the predic-
tion of functional recovery after revascularization (1–8). In
these studies, high sensitivity and specificity to predict
functional outcome were reported. However, several aspects
of the usefulness of DSE need further study. First, most
studies have included patients with mild to moderate left
ventricular (LV) dysfunction. Assessment of viable myocar-
dium and prediction of functional recovery after revascular-
ization, however, bears most clinical relevance in patients
with severely depressed LV function, because these patients
are exposed at high risk when undergoing revascularization
(9,10). Second, most studies have focused on regional LV
function instead of global LV function (whereas recovery of
global LV function has the most clinical relevance). Third,
studies exploring the relation between the amount of viable
myocardium and the magnitude of improvement of LV
ejection fraction (LVEF) are scarce, as pointed out recently
by Rahimtoola (11); the exact amount of viable tissue
needed to result in improvement of LVEF is not known.
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For clinical patient management, this information would be
extremely valuable. Fourth, no studies with DSE have
focused on prediction of improvement of functional status
(which may clinically be more relevant than improvement of
LVEF). Finally, long-term follow-up studies of patients
with and without viability are scarce for DSE. We have
addressed these issues in the present study. A total of 76
patients with poor LV function (LVEF 35% or less) were
screened; follow-up of global LV function was related to the
presence of viability. The relation between the extent of
viability and the magnitude of improvement of LVEF was
assessed. Next, receiver operating characteristic (ROC)
curve analysis was performed to identify a cutoff value of
viable myocardium needed to result in improvement of
LVEF after revascularization. Using this cutoff value to
separate the patients into “viable and nonviable patients,”
the influence of viability on improvement of functional
status and long-term prognosis was evaluated.
METHODS
Patients, Study Protocol
Patients were eligible if they fulfilled the following inclusion
criteria:
1. stable, chronic coronary artery disease;
2. depressed LV function on LV ventriculography (LVEF
35% or less);
3. already scheduled for revascularization (percutaneous
transluminal coronary angioplasty/coronary artery bypass
grafting [CABG]);
4. no significant valvular disease (patients with 3–41
(moderate–severe) mitral insufficiency were excluded),
and
5. adequate acoustic window to allow DSE.
The results of DSE did not influence the decision to
revascularize. Within one month before revascularization
radionuclide ventriculography (RNV), echocardiography
and combined low–high dose DSE were performed. Three
months after the revascularization, echocardiography and
RNV were repeated. The protocol was approved by the local
Medical Ethics Committee (ThoraxCenter Rotterdam) and
each patient gave informed consent before the test was
started.
Dobutamine Echocardiography
Beta-adrenergic blocking agents were withdrawn 36 h
before DSE; other cardiac medications were continued.
Low–high dose DSE (up 40 mg/kg/min with addition of
1 mg atropine if necessary) was performed as described
previously (12). The interpretation of the DSE studies was
performed by three experienced observers blinded to the
clinical data. Good inter- and intraobserver agreement for
the analysis of DSE was reported previously (92% and 94%
respectively) (3). For analysis of echocardiograms a 16-
segment model was used (13). Segmental wall motion/
thickening was scored on a five-point scale: 1 5 normal,
2 5 mildly hypokinetic, 3 5 severely hypokinetic, 4 5
akinetic and 5 5 dyskinetic. Wall thickening was primarily
utilized for the classification, preempting the problem of
postoperative paradoxical septal motion. To reduce the
confounding effect of tethering, segmental wall thickening
was analyzed frame by frame during the first half of systole.
The studies were analyzed using the digitized rest, low and
high dose dobutamine images, displayed in a quad-screen
format and by reviewing the videotapes. Four different
patterns were observed in the segments that were dysfunc-
tional at baseline:
1. Biphasic response: improvement of wall motion during
low dose (either at 5 or 10 mg) followed by worsening of
wall motion during high dose dobutamine.
2. Sustained improvement: improvement at low or high
dose dobutamine without deterioration of wall motion.
3. Worsening: deterioration of wall motion during either
low or high dose dobutamine.
4. No change: absence of improvement or worsening dur-
ing the entire test.
Dysfunctional segments were classified viable when they
exhibited any of the patterns except for the “no change
pattern.”
Assessment of Baseline
Dysfunction and Functional Outcome
Regional LV function. Regional function was assessed by
resting echocardiography before and three months after the
intervention. A 16-segment model was used, and each
segment was scored as described under the subheading
“Dobutamine Echocardiography” (inter- and intraobserver
agreement for assessing resting wall motion were 84% and
87% [3]). Improvement of regional function was considered
when wall motion improved by one grade or more; improve-
ment from dyskinesia to akinesia was not considered im-
provement.
Global LV function. Global function was assessed by
RNV at rest (before and three months after revasculariza-
tion) in 46 patients as described previously (2). In the
remaining patients the LVEF, before and after the revas-
cularization, was calculated by cross-sectional echocardiog-
raphy utilizing the apical biplanar Simpson’s technique (13).
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CCS 5 Canadian Cardiovascular Society
CI 5 confidence interval
DSE 5 dobutamine stress echocardiography
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
RNV 5 radionuclide ventriculography
ROC 5 receiver operating characteristic
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Each patient had the same technique to assess LVEF before
and after the revascularization, to avoid comparison of
LVEFs obtained by different techniques. Improvement of
global function after revascularization was defined as an
increase of LVEF $5%, as used previously (1,2,7,14).
Assessment of Functional Status and Long-Term Follow-up
Functional status was assessed according to the New York
Heart Association (NYHA) criteria (for symptoms of heart
failure) and according to the Canadian Cardiovascular
Society (CCS) classification (for angina pectoris). In each
patient, the functional status before and three months after
revascularization was determined by interviews and physical
examinations conducted by an investigator blinded to the
DSE and LVEF data. The long-term follow-up was per-
formed by chart review and telephone contact. Follow-up
data (NYHA functional class, CCS classification and events)
were acquired up to two years. Early events were as follows:
in-hospital mortality/infarction and low output syndrome
(diagnosed when high inotropic medication or intra-aortic
balloon pumping were used to sustain adequate hemody-
namic status [15]). Late events were as follows: cardiac death
(defined by the hospital chart documenting arrythmic death or
death attributable to congestive heart failure, myocardial
infarction or cardiac arrest), nonfatal myocardial infarction
and congestive heart failure requiring hospitalization.
Statistical Analysis
Continuous data were expressed as mean 6 SD and
compared using the Student t test for paired and unpaired
data when appropriate. Univariate analysis for categorical
variables was performed using the chi-square test with
Yates’ correction. The relation between the number of
dysfunctional, viable segments on DSE and the magnitude
of improvement of LVEF after the revascularization was
determined by the Kruskal-Wallis test. The optimal number
of viable segments on DSE (discriminating between pa-
tients with and without improvement of LVEF after revas-
cularization) was determined by ROC curve analysis. The
optimal cutoff value (number of segments) was defined as
that providing the maximal sum of sensitivity/specificity.
Sensitivity, specificity and positive and negative predictive
values are based upon their standard definitions and pre-
sented with their 95% confidence intervals (CIs). According
to this cutoff value (number of viable segments on DSE),
the patients were divided into two groups (viable and
nonviable patients). The event-free (for definition of events
see above) survival of these two groups of patients was
compared using Kaplan-Meier curves. Differences between
event-free survival curves were tested with the log-rank
chi-square statistic. For all tests, a p value ,0.05 was
considered significant.
RESULTS
Study population. A total of 76 patients were included in
the study; eight patients had LV aneurysmectomy (n 5 4)
or absence of functional follow-up (n 5 4). None of the
remaining 68 patients had a myocardial infarction or an
episode of unstable angina/heart failure requiring hospital-
ization before revascularization. Revascularization was es-
tablished by CABG in 60 patients and by angioplasty in
eight patients. Indications for revascularization were heart
failure in 36 and angina pectoris in 32. There were 57 men
with a mean age of 61 years (range 43 to 79). Sixty-five
(96%) had a previous infarction (.3 months before the
study), and 55 exhibited Q waves on the electrocardiogram
(29 anterior, 19 inferior and 7 both). They had on average
2.5 6 0.7 stenosed vessels. Ten patients had diabetes
mellitus type II and 13 had systemic hypertension.
Six patients were not studied after revascularization be-
cause of perioperative infarction (n 5 2)/death (n 5 1) or
in-hospital death (n 5 3). Because no regional wall motion
and LVEF were assessed after revascularization in these six
patients, the comparison between baseline data and three-
month follow-up data was limited to the remaining 62
patients; the indication for revascularization in the six
excluded patients was heart failure in four and angina
pectoris in two. For the long-term follow-up, however, all
68 patients were included. None of the patients was referred
for heart transplantation after revascularization.
Baseline function versus functional outcome. A total of
992 segments were analyzed (in 62 patients), with 554
(56%) demonstrating abnormal wall motion. Twenty-three
were not revascularized adequately (based upon review of
the CABG/angioplasty reports), leaving 531 segments for
the analysis. Baseline dysfunction included dyskinesia in 9
(2%) segments, akinesia in 214 (40%), severe hypokinesia in
108 (20%) and mild hypokinesia in 200 (38%) segments.
Improvement of wall motion occurred in 141 (27%) seg-
ments, including 61 mild hypokinetic, 44 severe hypokinetic
and 36 akinetic segments (p , 0.01 vs. [mild] hypokinetic
segments). None of the dyskinetic segments improved in
function. None of the nonrevascularized segments improved
in function. Baseline LVEF ranged from 13% to 35%. In
the entire group the LVEF did not improve significantly
(28 6 6% vs. 30 6 7%, p 5 NS). The LVEFs before and
after revascularization of the individual patients are demon-
strated in Figure 1. Twenty-one patients improved $5% in
LVEF after the revascularization (from 26 6 7% to 34 6
7%). Forty-one patients did not improve their LVEF $5%
(29 6 5% vs. 28 6 5%).
Dobutamine echocardiography versus functional out-
come. The distribution of the different responses in dys-
functional segments to low–high dose dobutamine is dem-
onstrated in Figure 2. Dopamine stress echocardiography
had a sensitivity of 89% (125/141, 95% CI 84% to 94%) and
a specificity of 74% (287/390, 95% CI 70% to 78%), with a
positive predictive value of 55% (125/228, 95% CI 49% to
61%) and a negative predictive value of 95% (287/303, 95%
CI 92% to 98%) to predict improvement of regional LV
function. There was a significant relation between the
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number of viable segments (per patient) on DSE and the
magnitude of improvement in LVEF after revascularization:
y 5 1.37* 3 22.04 (p , 0.001, r 5 0.70, n 5 62). The
number of scar segments was not significantly related to the
change in LVEF.
The ROC curve analysis showed that the cutoff value of
four dysfunctional but viable segments yielded the highest
sensitivity/specificity (Fig. 3); 18 of 21 patients with an
improvement of LVEF after the revascularization had $4
viable segments, whereas only four patients with $4 viable
segments did not improve (p , 0.05). Using this cutoff
level, DSE had a sensitivity of 86% (95% CI 71% to 100%)
and a specificity of 90% (95% CI 81% to 99%), with a
negative predictive value of 93% (95% CI 85% to 100%) and
a positive predictive value of 82% (95% CI 76% to 88%) to
predict improvement of LVEF.
Accordingly, the patients were divided into two groups.
Group A consisted of 22 patients (18 undergoing CABG,
four undergoing angioplasty) with $4 viable segments on
DSE; group B consisted of 40 patients (36 undergoing
CABG, four undergoing angioplasty) with ,4 viable seg-
ments (Table 1). In group A the LVEF increased signifi-
cantly after revascularization; the NYHA functional class
and the CCS classification also improved significantly. Of
the 13 patients (12 undergoing CABG, one undergoing
angioplasty) presenting with heart failure symptoms, 12
(92%, 11 undergoing CABG, one undergoing angioplasty)
improved their NYHA functional class by one grade or
more (Fig. 4). All patients (n 5 9, six undergoing CABG,
three undergoing angioplasty) presenting with angina pec-
toris improved their CCS classification by one grade or
more. In group B the LVEF did not improve after revas-
Figure 1. Scatter plot showing the individual LVEFs before and
after revascularization. Improvement of LVEF occurred over the
entire range of LVEFs. The solid line represents the line of
identity. LVEF 5 left ventricular ejection fraction; post: after
revascularization; pre 5 before revascularization. Triangles 5
improvers; octagons 5 nonimprovers.
Figure 2. Pie chart demonstrating the distribution of the different
responses during dobutamine stress echocardiography.
Figure 3. Receiver operating characteristic curve analysis showing
that the cutoff level of four dysfunctional but viable segments
yielded the highest sensitivity/specificity to predict functional
outcome on a patient basis.
Table 1. Differences Between Patients With $4 Viable








Age (yr) 61 6 9 62 6 9 NS
Gender (M/F) 19/3 33/7 NS
Q-wave MI 13 (59%) 36 (90%) ,0.01
VD 2.5 6 0.7 2.5 6 0.7 NS
DM 1 (5%) 7 (18%) NS
HT 6 (27%) 6 (15%) NS
Clinical presentation
AP 9 (41%) 21 (52%) NS
HF 13 (59%) 19 (48%) NS
LVEF pre (%) 27 6 6* 28 6 5 NS
LVEF post (%) 33 6 7 28 6 5 ,0.01
NYHA pre 3.2 6 0.7* 3.1 6 0.5 NS
NYHA post 1.6 6 0.5 2.8 6 0.7 ,0.01
CCS pre 2.9 6 0.3* 3.0 6 0.8* NS
CCS post 1.2 6 0.4 1.3 6 0.5 NS
*p , 0.01 pre- vs. postrevascularization values.
AP 5 angina pectoris; CCS 5 Canadian Cardiovascular Score; DM 5 diabetes
mellitus; HF 5 heart failure; HT 5 systemic hypertension; LVEF 5 left ventricular
ejection fraction; MI 5 myocardial infarction; NYHA 5 New York Heart Association;
post 5 after revascularization; pre 5 before revascularization; VD 5 vessel disease.
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cularization; the NYHA functional class remained un-
changed, whereas the CCS classification improved signifi-
cantly. Of the 19 patients (17 undergoing CABG, two
undergoing angioplasty) presenting with heart failure symp-
toms, four (21%, all undergoing CABG) improved their
NYHA functional class one grade or more (p , 0.05 vs.
group A, Fig. 4). Of the 21 patients (19 undergoing CABG,
two undergoing angioplasty) presenting with angina pecto-
ris, 19 (90%, 17 undergoing CABG, two undergoing
angioplasty) improved their CCS classification by one grade
or more (p 5 NS vs. group A).
Dobutamine echocardiography versus long-term follow-
up. The duration of follow-up was 18.7 6 8.1 months. A
total of 25 events occurred in 68 patients. The early events
included four cardiac deaths, two nonfatal infarctions and
four low output syndromes. The late events included two
cardiac deaths, four nonfatal infarctions and nine episodes
of congestive heart failure.
Five of the six patients who were excluded from the
three-month follow-up analysis (see above) had ,4 viable
segments on DSE and were thus assigned to group B; the
remaining patient had $4 viable segments and was assigned
to group A. The distribution of events in groups A and B is
shown in Table 2. The number of hard events was not
significantly different between the two groups; the entire
event rate however was significantly higher in group B as
compared with group A (17% vs. 47%, p , 0.05) as
evidenced by Kaplan-Meier analysis (p 5 0.02 by log-rank
test, see Fig. 5). After 12 months, the event-free survival
was 87% (SE 7%) in group A and 71% (SE 7%) in group B.
After 24 months, the event-free survival was 82% (SE 8%)
in group A and 53% (SE 7%) in group B.
In group A, the NYHA functional class remained im-
proved at two years (3.2 6 0.7 vs. 1.6 6 0.6, p , 0.01). The
CCS classification also remained improved (2.9 6 0.3 vs.
1.3 6 0.4, p , 0.01). In group B, the NYHA functional
class remained unchanged at 2 years (3.1 6 0.5 vs. 2.9 6
1.0, p 5 NS). The CCS classification remained improved
(3.0 6 0.8 vs. 1.4 6 0.5, p , 0.01).
DISCUSSION
Dobutamine stress echocardiography showed a high sensi-
tivity and specificity to predict improvement of regional LV
function. The number of viable segments on DSE was
linearly related to the magnitude of improvement of LVEF.
The ROC curve analysis showed that the cutoff value of four
dysfunctional but viable segments (25% of the LV) yielded
the highest sensitivity/specificity to predict improvement
of global LV function: 86% versus 90%. Patients with $4
viable segments showed improvement in heart failure symp-
toms and had a significantly lower event rate during 2-year
follow-up (as compared with patients with ,4 viable
segments on DSE). Improvement of angina pectoris was
not related to the presence or absence of viability, because
the CCS score improved after revascularization in patients
with and without substantial viability.
Findings in the Present Study
Incidence of recovery. In the present study, 27% of the
dysfunctional segments improved after revascularization, in
Figure 4. Change in NYHA functional class in the two groups
after revascularization. In group A (patients with $4 viable
segments) mean NYHA functional class improved from 3.2 to 1.8.
In group B (patients with ,4 viable segments) the mean NYHA
functional class remained unchanged (from 3.1 to 2.8). NYHA 5
New York Heart Association; post 5 after revascularization; pre 5
before revascularization.
Figure 5. Event-free survival curves of the patients in the two groups.
The event rate was higher in group B (p 5 0.02 vs. group A).
Table 2. Events in Patients With $4 Viable Segments (Group
A, n 5 23) and ,4 Viable Segments (Group B, n 5 45) on
Dobutamine Stress Echocardiography
Group A Group B
Early events
Cardiac death — (0%) 4 (9%)
Infarction 1 (4%) 1 (2%)
Low output syndrome — (0%) 4 (9%)
Late events
Cardiac death 1 (4%) 1 (2%)
Infarction 1 (4%) 3 (7%)
Episode of heart failure 1 (4%) 8 (18%)
Total events 4 (17%)* 21 (47%)
*p , 0.05 vs. group B.
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line with previous results (16). Improvement was observed
more frequently in the segments with mild dyssynergy
(hypokinesia or mild hypokinesia) as compared with the
segments with more severe dyssynergy, as reported by others
(3,8). The incidence of improvement of global LV function
(34% of patients) was comparable to the incidence of
regional improvement; the findings suggest that a substan-
tial amount of hibernating myocardium occurs in approxi-
mately one third of the patients. Moreover, as depicted in
Figure 1, improvement occurred over the entire range of
LVEFs, emphasizing that improvement of LVEF is not
limited to patients with relatively preserved LV function.
Relation between viability and recovery. In the present
study, approximately 90% of the viable segments improved
in function after the revascularization; almost 75% of the
segments without viability did not improve. A comparable
sensitivity with a somewhat lower specificity was presented
by Meza et al. (17), who studied a similar cohort of patients.
The imperfect diagnostic accuracy of both studies may be
related to several factors: 1) longer follow-up is needed; 2)
occurrence of periprocedural necrosis resulting in absence of
recovery in viable segments, and 3) false positive responses
to dobutamine caused by tethering or occurring in the
presence of subendocardial scar (18). The lower specificity
in the study by Meza et al. (17) may further be related to the
subtle differences in study protocols and viability criteria
used.
In contrast with the large number of studies that have
evaluated the use of DSE to predict improvement of
regional LV function (19), only few studies have focused on
prediction of improvement of global LV function (8), and
most studies have included patients with a mildly depressed
LV function. This study provides data in a large group of
patients, all with severely depressed LV function. On a
global basis, ROC curve analysis showed that application of
a cutoff level of $4 viable segments on DSE (representing
$25% of the LV) yielded the highest diagnostic accuracy to
predict improvement of LVEF (Fig. 3). Intraobserver and
interobserver agreement for this cutoff level were deter-
mined in 30 patients and were 97%, and 93%, respectively.
Using the four-segment cutoff level, a sensitivity of 86% and
a specificity of 90% were obtained. Nagueh and coworkers
(8) studied 18 patients and showed that all individuals with
a significant improvement in LVEF after revascularization
had $4 viable segments on DSE. These findings imply that
a substantial amount of viable myocardium needs to be
present to establish improvement of global LV function
after revascularization. Moreover, the magnitude of im-
provement of LVEF was linearly related to the number of
viable segments on DSE. In contrast, the improvement of
LVEF was not related to the number of scar segments.
Relation between viability and improvement of symp-
toms. In this study, the presence of viable myocardium was
linked not only to improvement of function, but also to
improvement of heart failure symptoms. The data demon-
strate that patients with a substantial amount of viable
myocardium ($25% of the LV, group A) are likely to
improve in heart failure symptoms. The results are in line
with those reported by Di Carli et al. (20). The authors
showed, by applying ROC curve analysis, that 18% viable
myocardium best predicted improvement of heart failure
symptoms. Clinically, improvement in the quality of life
(reflected by a reduction in heart failure symptoms) may be
more important than the improvement in LVEF, as pointed
out recently by Bonow (21). Hence, the presence of sub-
stantial viability in patients presenting with heart failure
may be an indication for revascularization, as indicated
recently by Marwick (22) and Beller (23).
Of interest, 21% of the patients with ,4 viable segments
(group B) also improved in heart failure symptoms (only one
of these patients improved in LVEF after revascularization).
This observation is in close agreement with data reported
recently by Lombardo et al. (24) showing that 22% of the
patients without substantial viability on DSE demonstrated
improvement of heart failure symptoms. It is plausible that
in these patients, the improvement of heart failure symp-
toms was related more to revascularization of regions with
stress-inducible ischemia (leaving resting LVEF unchanged
after revascularization) than to revascularization of hiber-
nating myocardium (improving resting LVEF after revas-
cularization). This phenomenon can be tested by perform-
ing low–high dose DSE before and after revascularization,
as recently reported by Afridi et al. (25). Therefore, the
LVEF during stress may be a more optimal end point after
revascularization than the assessment of resting LVEF, as
already suggested by Kaul (26). Further studies are needed
to elucidate these issues.
Long-term follow-up. Overall survival independent of the
viability status in patients with severely depressed LV
function was good after revascularization, comparable to
previous results (27). However, in group A, significantly
fewer events occurred (17% vs. 47%). These data are in
line with recent studies using nuclear imaging techniques
(28) and DSE (29,30). Pagley et al. (28) studied 70 patients
with chronic coronary artery disease and LVEF ,40%
with thallium-201 scintigraphy before revascularization.
The authors showed that patients without substantial
viability had a very high event rate at long-term follow-up.
These findings and our results indicate that viability assess-
ment may be very useful in preoperative risk stratification.
Moreover, Haas et al. (15) showed that significantly fewer
events occurred in patients undergoing revascularization,
when preoperative viability assessment (using F18-
fluorodeoxyglucose and positron emission tomography) was
performed. In addition to event-free survival benefit in
patients with substantial viability, we also showed that
symptoms of heart failure decreased in these patients and
that the improvement in NYHA functional class was
maintained during the two-year follow-up period.
168 Bax et al. JACC Vol. 34, No. 1, 1999
Prognosis vs. Myocardial Viability July 1999:163–9
Limitations
Several limitations of the current study need to be ad-
dressed. First, repeat angiography or some form of stress
testing after the intervention was not performed, therefore
we cannot ascertain adequate revascularization of all seg-
ments. Reocclusion may have prevented some viable seg-
ments from recovering and may have influenced the results.
Second, functional follow-up was limited to three months,
whereas longer follow-up may be necessary for some seg-
ments to improve function. Third, it has been questioned
recently whether end points other than improvement of
function after revascularization should be used to assess the
clinical benefit of revascularization (21). In addition to
improvement of heart failure symptoms, these end points
include improvement of exercise capacity and the relation
between viability and prevention of LV dilation and remod-
eling after revascularization. The relation between the pres-
ence of viability before the revascularization and these
aspects needs further study.
Conclusions. In the present study, it has been demon-
strated that the presence of substantial viability on DSE is
associated with improvement in LVEF and heart failure
symptoms after revascularization, and is accompanied by a
favorable prognosis. Hence, viability testing by DSE may
guide therapeutic management in patients with severely
ischemic LV dysfunction.
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